Skip to main
COYA

COYA Stock Forecast & Price Target

COYA Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Coya Therapeutics is showing strong potential for success as a clinical-stage biotechnology company with a focus on developing therapies targeting regulatory T cells. The company's diversity of potential treatments, as well as its partnerships and combination strategies, suggest strong potential for future growth. Additionally, the recent biomarker publications strengthen the company's scientific foundation and provide external validation for its approach, making it an attractive investment opportunity.

Bears say

Coya Therapeutics is a development stage company that currently does not have any products generating revenue, indicating potential financial instability. The company will likely need to raise additional capital through debt or equity funding, which may be dilutive to stockholders. Additionally, the company faces significant competition in the biotechnology and pharmaceutical industries, and the development of new treatment methods for its target diseases could render its therapies non-competitive. The company's therapeutic products also face clinical and regulatory risks, as well as fluctuating valuations due to the complexity of accurately valuing a development stage company. Finally, while the company's approach may have potential, validation of its biological underpinnings does not guarantee clinical success, and the company's current focus on targeting Treg dysfunction may be limited in its applicability to other diseases.

COYA has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Coya Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Coya Therapeutics Inc (COYA) Forecast

Analysts have given COYA a Strong Buy based on their latest research and market trends.

According to 5 analysts, COYA has a Strong Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Coya Therapeutics Inc (COYA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.